Anúncio
Anúncio

ALGS

ALGS logo

Aligos Therapeutics, Inc. Common Stock

10.21
USD
Patrocinado
+0.55
+5.75%
08 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

9.99

-0.21
-2.11%

Relatórios de Lucros ALGS

Rácio de surpresa positiva

ALGS separação 11 de 21 últimas estimativas.

52%

Próximo Relatório

Data do Próximo Relatório
09 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$816.00K
/
-$1.60
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+10.12%
/
-47.37%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+29.73%
/
-52.94%

Aligos Therapeutics, Inc. Common Stock earnings per share and revenue

On 06 de nov. de 2025, ALGS reported earnings of -3.04 USD per share (EPS) for Q3 25, missing the estimate of -1.93 USD, resulting in a -56.86% surprise. Revenue reached 741.00 mil, compared to an expected 510.00 mil, with a 45.29% difference. The market reacted with a -3.14% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analistas forecast an EPS of -1.60 USD, with revenue projected to reach 816.00 mil USD, implying an diminuir of -47.37% EPS, and aumentar of 10.12% in Revenue from the last quarter.
FAQ
For Q3 2025, Aligos Therapeutics, Inc. Common Stock reported EPS of -$3.04, missing estimates by -56.86%, and revenue of $741.00K, 45.29% above expectations.
The stock price moved down -3.14%, changed from $7.33 before the earnings release to $7.10 the day after.
The next earning report is scheduled for 09 de mar. de 2026.
Based on 6 analistas, Aligos Therapeutics, Inc. Common Stock is expected to report EPS of -$1.60 and revenue of $816.00K for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio